Generating hepatitis B and D monitoring indicators in Germany using claims data: number of persons tested, incident and prevalent infections, 2016–2021 - Report - MDSpire
Advertisement
Generating hepatitis B and D monitoring indicators in Germany using claims data: number of persons tested, incident and prevalent infections, 2016–2021
Monitoring Indicators for Hepatitis B and D in Germany Derived from Claims Data
Overview
This study evaluates the use of claims data to monitor hepatitis B and D indicators in Germany from 2016 to 2021. It highlights the annual testing rates and prevalence of infections.
Background
Hepatitis B virus (HBV) infection is a significant global health issue, affecting over 250 million individuals. The World Health Organization (WHO) has set a goal to eliminate viral hepatitis as a public health threat by 2030, emphasizing the need for comprehensive monitoring systems. In Germany, existing data sources are limited, necessitating alternative methods like claims data to assess hepatitis prevalence and testing rates.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
Claims data can provide insights into the annual number of persons tested for HBV and HDV.
Prevalent and newly detected HBV infections were assessed using claims data.
HDV infections among HBV-positive individuals were also evaluated.
The study discusses the plausibility of trends observed in claims data compared to national data sources.
Linkage to care could not be directly assessed due to limitations in claims data.
Clinical Implications
The findings suggest that claims data may serve as a valuable resource for monitoring hepatitis indicators, which is crucial for public health strategies. Enhanced data collection could improve understanding of hepatitis prevalence and inform healthcare responses.
Conclusion
The study demonstrates the potential of claims data to supplement existing hepatitis surveillance efforts in Germany, highlighting the need for improved data collection systems.
